Categories U.S. Markets News

Will the stock indexes rise in March?

US equities had dropped sharply in February as wage hike prompted investors to analyze the Federal Reserve’s proposed policy tightening pace. So will the indexes reverse the decline in March?

According to market gurus, economic activity could face a slowdown due to the impact of consumer spending as higher interest rates will create more expensive borrowing. The weakness could aid rallying of indexes; there are also chances of a rebound if GDP growth remains strong in spite of aggressive rate hikes.

Schroder Investment Management North America expects interest rates to reach 3% by the end of 2019. The firm believes the Fed has now started a balance sheet reduction, and with core inflation rising, the firm expects four more rate hikes in 2018 and two in 2019.

Picture Courtesy: Wikipedia

However, from the recent developments, the equity market could be impacted by the newly imposed import steel and aluminum tariffs and could lead to a trade war in the economy.

In contrast, the US dollar index recovered in February, after a continuous fall in December and January hurt by the delay in various economic reforms. The Fed rate hikes expectations in the near future could help in a rise in the dollar index in February.

 

The Fed rate hikes expectations in the near future could help in a rise in the dollar index in February.

According to Financial Forecast Center, for the month of March, Dow Jones Industrial Average is expected to rise to about 25,180; S&P 500 is predicted to rise to 2,726; and Nasdaq composite is anticipated to see a growth of 7,240. So far in March, Nasdaq remained the most outperformed index with 1.90% growth, followed by S&P 500 (up 0.79%) and Dow Jones (down 0.60%).

In February, all indexes had shown weakness, with S&P 500 down 3.8%, Dow Jones slipping 4.2% and Nasdaq declining 1.8%.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top